Introduction {#section1-1557988316667692}
============

Testosterone is an anabolic hormone produced by testicular Leydig cells and regulated by the hypothalamic--pituary--gonadal axis ([@bibr36-1557988316667692]). Testosterone stimulates and modulates the development of muscles, bone, fat metabolism, skin, and adult male reproductive health ([@bibr23-1557988316667692]). It is well established that testosterone concentration decrease in men with aging ([@bibr39-1557988316667692]; [@bibr45-1557988316667692]). Low testosterone levels have been associated with cardiovascular conditions, increased insulin resistance, reduced bone mineral density, and increased fracture risk ([@bibr33-1557988316667692]; [@bibr37-1557988316667692]; [@bibr47-1557988316667692]). The negative effects of testosterone deficiency in bone metabolism have been related to increased levels of proinflammatory cytokines, such as interleukin-6, and enhanced osteoclastic activity ([@bibr17-1557988316667692]). Testosterone therapy presents positive effects on sexual function, body composition, and bone density in men, increasing the cortical bone size via stimulation of longitudinal and radial growth ([@bibr40-1557988316667692]; [@bibr53-1557988316667692]). A positive relationship between low serum testosterone levels and oral health has been suggested. [@bibr22-1557988316667692] reported a positive relationship between low testosterone serum levels and xerostomia associated with Sjogren's syndrome. [@bibr56-1557988316667692] evaluated the long-term effects of orchidectomy and low testosterone on the craniofaciodental development and maintenance of skeletal and oral health in rhesus macaques, reporting severe temporomandibular joint osteoarthritis, higher alveolar bone loss, and signs of severe periodontitis in the specimens with low testosterone levels.

Chronic periodontitis (CP) is an inflammatory condition of the tooth supporting structures (cementum, gingiva, periodontal ligament, and alveolar bone) that if left untreated progresses to bone destruction and tooth loss ([@bibr42-1557988316667692]). The relationship between female sex hormones (estrogens) and periodontal disease in women during puberty, pregnancy, and menopause, or taking oral contraceptives has been widely reported ([@bibr27-1557988316667692]; [@bibr46-1557988316667692]); however, only a limited number of studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr54-1557988316667692]; [@bibr55-1557988316667692]) have investigated the association between testosterone levels in men and CP. [@bibr20-1557988316667692] reported testosterone inhibitory properties in vitro in the cyclooxygenase pathway of arachidonic acid metabolism in gingiva. In one study ([@bibr50-1557988316667692]), testosterone reduced the osteoclast formation in a dose-dependent manner, and significantly influenced the production of tumor necrosis-α in rats. [@bibr21-1557988316667692] identified that men with prostate cancer undergoing androgen deprivation therapy were more likely to have periodontal disease (80.5%) than men without androgen deprivation therapy (3.7%). [@bibr48-1557988316667692] reported higher testosterone levels among men without tooth loss compared with subjects with tooth loss. However, conflicting results have also been reported. [@bibr41-1557988316667692] reported no significant difference in periodontal parameters, CP progression and tooth loss, independently of serum testosterone levels. Similar results were reported by [@bibr55-1557988316667692] and [@bibr34-1557988316667692]. Since the role of testosterone levels with reference to CP remains debatable, the aim of the present systematic review was to assess whether low testosterone levels in body fluids reflect CP in men.

Method {#section2-1557988316667692}
======

Focus Question {#section3-1557988316667692}
--------------

This systematic review was conducted by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines ([@bibr38-1557988316667692]). A specific question was constructed according to the Participants, Interventions, Control, and Outcomes principle. The focus question was "Is there a relationship between low testosterone levels in body fluids and CP?"

Literature Search Protocol {#section4-1557988316667692}
--------------------------

The international database of Prospectively Registered Systematic Reviews in Health and Social Care and the Cochrane Register of Systematic Reviews were searched in June 2016, and presented no existing or current review protocols assessing the relationship between CP and testosterone levels in men. An electronic search without time or language restrictions was conducted up to June 2016 using PubMed (National Library of Medicine), Google Scholar, Scopus, EMBASE, MEDLINE (Ovid), and Web of Knowledge databases, to identify studies relevant to the focus question. The following Medical Subject Headings (MeSH) were used: (a) periodontitis, (b) chronic periodontitis, (c) periodontal diseases, (d) testosterone, (e) gonadal steroid hormones, and the combinations a, b or c and d; and a, b or c and e. Other relevant non--Medical Subject Headings words were used in the search process to identify articles discussing periodontal parameters and/or gonadal steroid hormones. These included "bleeding on probing," "clinical attachment loss," "marginal bone loss," "tooth loss," "probing depth," and "sex hormones."

Titles and abstracts of studies identified using the above-described protocol were screened by two authors (SVK and GER) and checked for agreement. Full texts of studies judged by title and abstract to be relevant were read and independently evaluated for the stated eligibility criteria. Reference lists of potentially relevant original and review articles were hand-searched to identify studies that could have remained unidentified in the previous step. Once again, the articles were checked for disagreement via discussion among the authors (SVK and GER). Cohen kappa coefficients were used to determine the level of agreement between the two reviewers (kappa score = 0.90; [@bibr43-1557988316667692]). [Figure 1](#fig1-1557988316667692){ref-type="fig"} illustrates the literature search strategies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

![Article selection flow chart for the systematic review according to PRISMA guidelines.\
*Note*. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](10.1177_1557988316667692-fig1){#fig1-1557988316667692}

Eligibility Criteria {#section5-1557988316667692}
--------------------

The eligibility criteria were as follows: (a) original studies, (b) clinical studies, (c) case series, and (d) studies assessing the relationship between periodontal status and testosterone levels in men. Letters to the editor, case reports, commentaries, historic reviews, and experimental studies were excluded.

Quality Assessment {#section6-1557988316667692}
------------------

The studies that were included underwent a quality assessment with the Critical Appraisal Skills Program (CASP) Cohort Study Checklist ([@bibr58-1557988316667692]), in an attempt to increase the strength of the present systematic review. The CASP tool uses a systematic approach based on 12 specific criteria which are as follows: study issue is clearly focused (effect of testosterone levels in periodontal status); cohort is recruited in an acceptable way; exposure (testosterone levels in serum, gingiva, and/or saliva) is accurately measured; outcome (periodontal status) is accurately measured; confounding factors are addressed; follow-up is long and complete; results are clear; results are precise; results are credible; results can be applied to the local population; results fit with available evidence; and there are important clinical implications. Each criterion had a response of "Yes," "No," or ''Cannot tell." Each study had a possible maximum score of 12. CASP scores were used to grade the methodological quality of each study assessed in the present systematic review.

Results {#section7-1557988316667692}
=======

Study Selection and Characteristics {#section8-1557988316667692}
-----------------------------------

Four hundred and thirty-three potential articles were initially identified. After reviewing the abstracts, 410 publications which did not fulfill the eligibility criteria were excluded. In the second step, 15 more articles were excluded because they did not answer the focus question, were experimental studies, reviews, or studies conducted in children (younger than 12 years old) and/or women (see the [appendix](#app1-1557988316667692){ref-type="app"}). A total of eight studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]) were included in the present systematic review and processed for data extraction ([Figure 1](#fig1-1557988316667692){ref-type="fig"}).

All studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]) had a cross-sectional design and were performed on men under health care or university settings. These primary studies were conducted in the following countries: Germany, India, Turkey, and the United States. The number of study participants ranged from 24 to 1,838 male individuals with ages ranging from 15 years to 95 years, and a mean age ranging from 20.50 ± 0.67 years to 76.4 years. In six studies ([@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]), the participants were systemically healthy individuals. [@bibr19-1557988316667692] assessed periodontal status in patients with hypergonadotropic hypogonadism (HH), and [@bibr54-1557988316667692] studied testosterone levels associated to periodontal status in patients with diabetes mellitus (DM).

Periodontal Status and Testosterone Level Measurement {#section9-1557988316667692}
-----------------------------------------------------

In all studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]), intraoral examination was conducted to assess the patient's periodontal status. Probing depth (PD) and clinical attachment loss (CAL) were reported in six studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr54-1557988316667692]) and five studies ([@bibr19-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]), respectively. [@bibr34-1557988316667692] and [@bibr55-1557988316667692] determined periodontal tissue health using Russell's periodontal index (based on gingival inflammation and loss of periodontal attachment, used mainly for epidemiological purposes). Teeth mobility was reported in three studies ([@bibr34-1557988316667692]; [@bibr48-1557988316667692]; [@bibr54-1557988316667692]) and number of lost teeth was assessed in two studies ([@bibr41-1557988316667692]; [@bibr44-1557988316667692]). Other periodontal parameters reported include oral hygiene index of Greene and Vermillion ([@bibr55-1557988316667692]), plaque index ([@bibr19-1557988316667692]), gingival index (GI; [@bibr19-1557988316667692]; [@bibr54-1557988316667692]), and bleeding on probing (BOP; [@bibr19-1557988316667692]). In four studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]) radiographs were used to assess alveolar bone loss and to diagnose CP. [@bibr54-1557988316667692] performed histological examination of paraffin secretions of gingiva to diagnose periodontitis.

Testosterone levels in serum were measured in seven studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]), out of which radioimmunoassay was used in three studies ([@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr55-1557988316667692]), and enzyme immunoassay in three studies ([@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]). [@bibr19-1557988316667692] did not report the method used to analyze testosterone levels in serum. [@bibr54-1557988316667692] measured testosterone levels in saliva using radioimmunoassay, and [@bibr34-1557988316667692] collected parotid saliva using a Carlson--Crittenden device and did not report the method to assess testosterone levels. [@bibr54-1557988316667692] obtained gingival tissue samples to assess in vitro the metabolism of testosterone in healthy and diseased gingiva. This significant heterogeneity among all the studies did not allow pooling of results and statistical analysis.

Confounding Factors {#section10-1557988316667692}
-------------------

In two studies ([@bibr34-1557988316667692]; [@bibr55-1557988316667692]) confounding variables were not assessed. [@bibr19-1557988316667692] assessed systemic disorders such as inflammatory, immune and hormonal conditions (other than HH), and exposure to antibiotics or periodontal therapy within the preceding 6 months. Likewise, [@bibr54-1557988316667692] excluded patients with systemic disorders; however, studied diabetic patients (type 1 and type 2 DM) requiring diet, insulin, or oral antihyperglycemic agents. Four studies ([@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]) assessed diverse confounders including race, education level, alcohol, drugs and tobacco exposure, systemic diseases, DM, and/or obesity (body mass index, physical activity, and/or waist circumference; [Table 1](#table1-1557988316667692){ref-type="table"}).

###### 

General Characteristics of the Studies Included.

![](10.1177_1557988316667692-table1)

  Authors (region of study)              Study groups                                        Age in years (range)       Periodontal status diagnosis method             Testosterone measurement method                          Confounding variables assessed
  -------------------------------------- --------------------------------------------------- -------------------------- ----------------------------------------------- -------------------------------------------------------- --------------------------------
  [@bibr19-1557988316667692]; Turkey)    48 Male                                             19-21                      Clinical examination (PI, GI, BOP, PD, CAL)     Serum (NA)                                               Systemic conditions
                                         Group 1: 12 HH + CP                                 Group 1: 20.83 ± 0.93                                                                                                               Periodontal therapy
                                         Group 2: 12 HH + HP                                 Group 2: 20.50 ± 0.67      Radiographs (FMX)                                                                                        
                                         Group 3: 12 SH + CP                                 Group 3: 20.58 ± 0.90                                                                                                               
                                         Group 4: 12 SH + HP                                 Group 4: 20.91 ± 0.93                                                                                                               
  [@bibr34-1557988316667692]; Turkey)    24 Male                                             Group 1: 30-40             Clinical examination (RPI, PD, mobility, MBL)   Serum: RIA                                               None
                                         Group 1: 14 CP                                      Group 2: 28-36                                                             Parotid saliva: Carlson--Crittenden device               
                                         Group 2: 10 HP                                                                 Radiographs                                                                                              
  [@bibr41-1557988316667692]; USA)       First exam: 1,210 Men                               First exam: 74.6 (66-95)   Clinical examination (tooth loss, CAL, PD)      Serum: RIA                                               Race
                                                                                                                                                                                                                                 Smoking
                                                                                                                                                                                                                                 BMI
                                         Second exam: 1,019 Men                              Second exam: 76.4          Education level                                                                                          
                                                                                                                                                                                                                                 Diabetes mellitus
  [@bibr44-1557988316667692]; Germany)   Group 1: 1,838 men for number of teeth              Group 1: 50 (36-63)        Clinical examination (tooth loss, CAL)          Serum: Competitive chemiluminescent enzyme immunoassay   Smoking
                                                                                                                                                                                                                                 Diabetes mellitus
                                                                                                                                                                                                                                 Physical activity
                                         Group 2: 1,548 men for CAL                          Group 2: 46 (34-59)                                                                                                                 Waist circumference
                                                                                                                                                                                                                                 Socioeconomic status
                                                                                                                                                                                                                                 Educational level
  [@bibr48-1557988316667692]; India)     203 SH + CP                                         45-65                      Clinical examination (CAL, PD, mobility)        Serum: Enzyme immunoassay                                Systemic conditions
                                                                                                                                                                                                                                 Smoking
                                         Group 1: Completely dentate and partially dentate                                                                                                                                       Alcohol
                                         Group 2: Tooth loss \<3 and \>3                                                                                                                                                         Medications
                                         Group 3: Tooth loss \<5 and \>5                                                                                                                                                         
  [@bibr51-1557988316667692]; USA)       755 Men                                             45 ± 0.5                   Clinical examination (CAL, PD)                  Serum: Competitive chemiluminescent enzyme immunoassay   Systemic conditions
                                                                                                                                                                                                                                 Race
                                                                                                                                                                                                                                 Diabetes mellitus
                                                                                                                                                                                                                                 Smoking
                                                                                                                                                                                                                                 Educational level
                                                                                                                                                                                                                                 BMI
                                                                                                                                                                                                                                 Alcohol
  [@bibr55-1557988316667692]; USA)       10 Males                                            Group 1:15-32 (31 ± 12)    Clinical examination(RPI, OHI)                  Serum: RIA                                               NA
                                         Group 1: RPI \<0.5                                  Group 2: 18-29 (20 ± 6)                                                                                                             
                                         Group 2: RPI 0.5-1.5                                Group 3: 18-19 (20 ± 3)    Radiographs                                     Gingiva: Histological evaluation                         
                                         Group 3: RPI 1.6-4                                                                                                                                                                      
  [@bibr54-1557988316667692]; USA)       40 Males                                            Group 1: 43 ± 13           Clinical examination (GI, PD, mobility)         Saliva: RIA                                              Systemic conditions
                                         Group 1: 8 SH + HP                                  Group 2: 45 ± 15           Radiographs (MBL)                                                                                        
                                         Group 2: 11 SH + CP                                 Group 3: 49 ± 13           Histological evaluation                                                                                  
                                         Group 3: 8 DM + HP                                  Group 4: 50 ± 14                                                                                                                    
                                         Group 4: 13 DM + CP                                                                                                                                                                     

*Note*. HH = hypergonadotropic hypogonadism; CP = chronic periodontitis; HP = healthy periodontum; SH = systemically healthy; PI = plaque index; GI = gingival index; BOP = bleeding on probing; PD = probing depth; CAL = clinical attachment loss; FMX = complete intra oral series; RIA = radioimmunoassay; BMI = body mass index; RPI = Russell's periodontal index; OHI = oral hygiene index; DM = diabetes mellitus; MBL = marginal bone loss; NA = not applicable.

Main Outcomes {#section11-1557988316667692}
-------------

### Serum Testosterone Levels {#section12-1557988316667692}

Four studies ([@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr55-1557988316667692]) reported a negative association between serum testosterone levels and periodontal inflammatory parameters. [@bibr41-1557988316667692] reported no significant difference in periodontal parameters (CAL, PD, and BOP), CP progression (odds ratio \[*OR*\] = 0.97, 95% confidence interval \[CI: 0.83, 1.14\]), tooth loss (*OR* = 1.01, 95% CI \[0.87, 1.18\]), and total testosterone levels in a cohort of 1,210 men followed for 3 years. Similarly, [@bibr44-1557988316667692] reported no consistent association of total testosterone levels and CAL, CP progression, and tooth loss (*OR* = 0.93, 95% CI \[0.80, 1.08\]) in a cohort of 1,838 men followed for 5 years.

Two studies ([@bibr48-1557988316667692]; [@bibr51-1557988316667692]) reported a positive association between decreased testosterone levels in serum and deteriorated periodontal parameters. [@bibr51-1557988316667692] reported that low total testosterone levels were associated with increased CP prevalence (*OR* = 2.1, 95% CI \[1.00, 4.5\]) and severity (*OR* = 2.1, 95% CI \[1.00, 4.3\]); and that lower levels of free and albumin-bound testosterone were associated with prevalence (*OR* = 3.9, 95% CI \[1, 15\]) and severity (*OR* = 3.4, 95% CI \[1.2, 9.8\]) of CP. Likewise, [@bibr48-1557988316667692] reported higher testosterone levels (4.41 ± 2.57) in subjects without tooth loss compared with subjects with tooth loss (2.79 ± 1.15).

[@bibr19-1557988316667692] reported that patients with HH (characterized by men with low levels of testosterone) and CP presented significantly higher GI and BOP compared with patients without HH with CP, suggesting a negative correlation between GI and free testosterone levels (*r* = −.794), and that testosterone may have an inhibitory effect on gingival inflammation. However, no significant difference in PD, CAL, and testosterone levels was reported.

### Saliva and Gingival Testosterone Levels {#section13-1557988316667692}

[@bibr34-1557988316667692] reported increased levels of testosterone in parotid saliva among patients with CP compared with patients with healthy periodontum. [@bibr54-1557988316667692] reported no significant difference in the concentration of salivary testosterone between patients with and without CP. However, in the study by [@bibr54-1557988316667692], higher levels of salivary testosterone were detected in patients with DM and CP. [@bibr55-1557988316667692] reported a significant increase in the overall metabolism of testosterone in the gingival tissue of patients with CP compared with healthy controls ([Table 2](#table2-1557988316667692){ref-type="table"}).

###### 

Primary Outcomes of the Studies Included.

![](10.1177_1557988316667692-table2)

  Relationship between male testosterone levels and periodontal disease                                                                               
  ----------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------
  [@bibr19-1557988316667692]                                              NA                                                                          Positive^[a](#table-fn3-1557988316667692){ref-type="table-fn"}^ (GI, BOP)
  Negative (CAL, PD)                                                                                                                                  
  [@bibr34-1557988316667692]                                              Positive^[b](#table-fn3-1557988316667692){ref-type="table-fn"}^ (saliva)    Negative
  [@bibr41-1557988316667692]                                              NA                                                                          Negative
  [@bibr44-1557988316667692]                                              NA                                                                          Negative
  [@bibr48-1557988316667692]                                              NA                                                                          Positive^[a](#table-fn3-1557988316667692){ref-type="table-fn"}^
  [@bibr51-1557988316667692]                                              NA                                                                          Positive^[a](#table-fn3-1557988316667692){ref-type="table-fn"}^
  [@bibr55-1557988316667692]                                              Positive^[b](#table-fn3-1557988316667692){ref-type="table-fn"}^ (gingiva)   Negative
  [@bibr54-1557988316667692]                                              Negative (saliva)                                                           NA

*Note*. GI = gingival index; BOP = bleeding on probing; PD = probing depth; CAL = clinical attachment loss; NA = not applicable.

Lower testosterone levels. ^b^Higher testosterone levels.

Quality Assessment of Included Studies {#section14-1557988316667692}
--------------------------------------

Quality scores of the studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]) ranged from 9 to 12. Quality assessment identified that in general, recruitment of the patients, exposure (measurement of testosterone levels), and outcome (periodontal status) were adequately performed in these studies. As only studies in human subjects were included, the results could be considered to be applicable to the local population. A common shortcoming among the studies was the omission of confounding variables assessment. This contributed to the difficulty in determining whether the results were in accordance with the available evidence. Quality assessment of the articles included in the systematic review is summarized in [Table 3](#table3-1557988316667692){ref-type="table"}.

###### 

CASP Quality Assessment of the Reviewed Articles.

![](10.1177_1557988316667692-table3)

  Authors                      Item 1   Item 2        Item 3        Item 4   Item 5        Item 6   Item 7   Item 8   Item 9   Item 10   Item 11   Item 12   Total quality score (0-12)
  ---------------------------- -------- ------------- ------------- -------- ------------- -------- -------- -------- -------- --------- --------- --------- ----------------------------
  [@bibr19-1557988316667692]   Yes      Yes           Cannot tell   Yes      No            No       Yes      Yes      Yes      Yes       Yes       Yes       9
  [@bibr34-1557988316667692]   Yes      Yes           Yes           Yes      No            No       Yes      Yes      Yes      Yes       Yes       Yes       10
  [@bibr41-1557988316667692]   Yes      Yes           Yes           Yes      Yes           Yes      Yes      Yes      Yes      Yes       Yes       Yes       12
  [@bibr44-1557988316667692]   Yes      Yes           Yes           Yes      Yes           Yes      Yes      Yes      Yes      Yes       Yes       Yes       12
  [@bibr48-1557988316667692]   Yes      Yes           Yes           Yes      Yes           No       Yes      Yes      Yes      Yes       Yes       Yes       11
  [@bibr51-1557988316667692]   Yes      Yes           Yes           Yes      Yes           Yes      Yes      Yes      Yes      Yes       Yes       Yes       12
  [@bibr55-1557988316667692]   Yes      Cannot tell   Yes           Yes      No            No       Yes      Yes      Yes      Yes       Yes       Yes       9
  [@bibr54-1557988316667692]   Yes      Yes           Yes           Yes      Cannot tell   No       Yes      Yes      Yes      Yes       Yes       Yes       10

*Note*. Item 1 = study issue is clearly focused; Item 2 = cohort is recruited in an acceptable way; Item 3 = exposure is accurately measured; Item 4 = outcome is accurately measured; Item 5 = confounding factors are addressed; Item 6 = follow-up is long and complete; Item 7 = results are clear; Item 8 = results are precise; Item 9 = results are credible; Item 10 = results can be applied to the local population; Item 11 = results fit with available evidence; Item 12 = there are important clinical implications.

Discussion {#section15-1557988316667692}
==========

A limited number of studies have suggested a relationship between common oral diseases such as CP and male reproductive health conditions, including erectile dysfunction, low testosterone levels, and male infertility ([@bibr19-1557988316667692]; Kellesarian, [@bibr31-1557988316667692]; [@bibr32-1557988316667692]; [@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]). To the best of our knowledge from indexed literature, this is the first study systematically reviewing the effect of testosterone levels in men's periodontal status. The purpose of this study was to highlight the use of testosterone levels as an analytical tool in the assessment of CP. Results from approximately 65% of the studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]) included reported a positive correlation between testosterone levels (saliva, gingiva, and/or serum) and CP. A possible explanation for these findings is related to an increased growth of periodontopathogenic bacteria and altered vasculogenesis stimulated by hormones ([@bibr51-1557988316667692]). It has been also proposed that testosterone could affect the gingival stromal cell response to inflammatory challenges by downregulation of proinflammatory cytokines production ([@bibr24-1557988316667692]). Other proposed mechanisms include exacerbated response in the periodontal tissue by immune--endocrine interactions and a hormonal modulation of specific cell lines (fibroblast and epithelial cells; [@bibr51-1557988316667692]). However, it is pertinent to mention that a variety of factors may have biased the results of the included studies, and these findings need to be interpreted with caution. First, notwithstanding immunoassays are considered a valid method to measure testosterone levels, the lack of standardization in steroid hormones assays is well documented in the literature and considered an important limitation and deficiency in many epidemiological studies ([@bibr16-1557988316667692]). The accuracy of immunoassays' measurements has been criticized when low testosterone concentrations are present, and high-quality steroid hormone assays with very good sensitivity, specificity, and reproducibility are required to the validate the data of epidemiologic studies ([@bibr49-1557988316667692]). Moreover, liquid chromatography--mass spectrometry is considered the gold standard and the only reliable method to measure sex steroids, including testosterone ([@bibr18-1557988316667692]; [@bibr52-1557988316667692]). On a vigilant evaluation of the studies included in the present systematic review, it was identified that approximately 88% of the studies ([@bibr34-1557988316667692]; [@bibr41-1557988316667692]; [@bibr44-1557988316667692]; [@bibr48-1557988316667692]; [@bibr51-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]) used different immunoassays to determine testosterone levels in serum and [@bibr19-1557988316667692] did not report the method used to assess testosterone levels. It is feasible that this lack of standardization in the methods to measure testosterone levels in serum may explain the conflicting results among the studies included. Well-designed prospective studies including liquid chromatography--mass spectrometry to assess testosterone levels are needed to draw definitive conclusions.

Second, several factors might influence testosterone levels, including aging, genetics, and comorbidities such as glycemic levels and obesity ([@bibr52-1557988316667692]). Furthermore, the aforementioned factors have been similarly associated with increased prevalence and severity of periodontitis ([@bibr25-1557988316667692]; [@bibr29-1557988316667692]; [@bibr30-1557988316667692]; Kellesarian, [@bibr31-1557988316667692]; [@bibr57-1557988316667692]). It is noteworthy that the age between the included studies varied significantly. [@bibr19-1557988316667692] studied men with HH with age ranged between 19 and 21 years. [@bibr34-1557988316667692] assessed testosterone levels in patients aged between 28 and 40 years, and [@bibr41-1557988316667692] studied men between 66 and 95 years. Furthermore, it is noteworthy that 50% among the studies included ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]) did not adjust the results for smoking, and approximately 63% of the studies ([@bibr19-1557988316667692]; [@bibr34-1557988316667692]; [@bibr48-1557988316667692]; [@bibr55-1557988316667692]; [@bibr54-1557988316667692]) remained unadjusted for obesity. It is speculated that low testosterone levels are simply a risk indicator for CP, originated from common exposures, such as chronic hyperglycemia, aging, obesity, and/or smoking. It is pertinent to mention that all the studies included were conducted for a relatively short period of time in only four countries, where the majority of the studies participants were of Caucasian origin. It is hard to generalize these findings to the whole population. Additional prospective studies including stringent confounder assessment, larger samples, for a longer period of time, and including different ethnicities are needed.

In two studies ([@bibr34-1557988316667692]; [@bibr54-1557988316667692]), testosterone levels were measured in whole saliva; however, the results were conflicting. [@bibr34-1557988316667692] reported a positive association between CP and higher salivary testosterone levels, whereas [@bibr54-1557988316667692] reported a negative association. The role of whole saliva as a diagnostic tool has gain popularity in the past decade due to its noninvasive accessibility ([@bibr28-1557988316667692]). The effectiveness of saliva as a reliable diagnostic fluid to measure testosterone levels remains debatable. For example, [@bibr26-1557988316667692] reported poor levels of agreement between saliva and serum measurements of testosterone among aging men, whereas [@bibr35-1557988316667692] reported a significant correlation between free testosterone in serum and saliva, whereas no significant correlation was reported between total testosterone in serum and saliva. Therefore, the authors of the present systematic review suggest extreme caution when interpreting the conclusions of the studies included in the present systematic review.

It is imperative for general physicians and oral health care providers to be aware of the fact that oral inflammatory conditions (such as CP) can influence the systemic health, including men's reproductive health. Likewise, systemic conditions (such as erectile dysfunction) may influence oral health status (Kellesarian, [@bibr31-1557988316667692]). It is therefore recommended that evaluations of patients' medical histories should be considered as an integral component of comprehensive dental examinations. Moreover, patients exhibiting low testosterone levels in body fluids should be referred to oral health care providers for dental examinations and treatment. Such regimens may also help improve the overall quality of life of patients.

Conclusion {#section16-1557988316667692}
==========

Within the limits of the evidence available, the relationship between low testosterone levels and CP remains debatable and further longitudinal studies and control trials are needed.
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